TP53 and metastatic colorectal cancer: This conclusion was to some extent supported by some prior studies evaluating the impact of TP53 mutation on the efficacy of bevacizumab combined with chemotherapy in other solid tumor types including metastatic colorectal cancer and advanced endometrial cancer [26, 27].